British drug giant GSK is reportedly in talks to acquire cancer drugmaker Nuvalent. The deal could be worth over nine billion dollars. Disc...

Tata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...

Biocon founder Kiran Mazumdar-Shaw has announced her successor. Niece Claire Mazumdar will lead the company. Claire Mazumdar is the founder...

Kiran Mazumdar-Shaw, the entrepreneurial force behind Biocon, has playfully dismissed claims that she proposed funding for Bengaluru's road...

Citi gave the buy rating after the company and Mylan announced launch of Ogivri in the US.

Buy Biocon Ltd. at a price target of Rs 660.0 and a stop loss at Rs 630 from the entry point.

Buy Biocon Ltd. at a price target of Rs 625.0 and a stop loss at Rs 594 from entry point.

Buy Biocon Ltd. at a price target of Rs 668.0 and a stop loss at Rs 622 from entry point.

Buy Biocon Ltd. at a price target of Rs 642.0 and a stop loss at Rs 606 from entry point.

Buy Biocon Ltd. at a price target of Rs 641.0 and a stop loss at Rs 620 from entry point.

Shaw recently recollected a personal memory to highlight her own run-in with the bias.

The award will be conferred on behalf of the President of the French Republic at a special ceremony later this year, Biocon said here in a ...

A made-to-scale stainless steel model of an aircraft, sculpted by artist Yusuf Arakkal, could soon adorn Minsk Square in the heart of Benga...

P M Murali, Managing Director and CEO, Evolva Biotech, was re-elected as President for a second term at the meet here last week, an ABLE re...

'Syngene is India’s leading research services company in discovery and development space, especially in the pharmaceutical sector,' says Ma...

Biocon chairman Kiran Mazumdar-Shaw was named to the board of directors of Infosys last week, the day the company saw one of its most high-...

Indian pharma firms are increasing their market presence globally. Read Biocon's next strategic plans.